Document and Entity Information
Document and Entity Information - shares shares in Thousands | 6 Months Ended | |
Jun. 30, 2019 | Aug. 02, 2019 | |
Document And Entity Information [Abstract] | ||
Entity Registrant Name | THERAPEUTICSMD, INC. | |
Entity Central Index Key | 0000025743 | |
Document Type | 10-Q | |
Trading Symbol | TXMD | |
Document Period End Date | Jun. 30, 2019 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity's Reporting Status Current | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | false | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 241,221,840 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2019 | |
Document Transition Report | false | |
Entity File Number | 001-00100 | |
City Area Code | 561 | |
Entity Address, Address Line Two | Third Floor | |
Entity Shell Company | false | |
Entity Tax Identification Number | 87-0233535 | |
Entity Incorporation, State or Country Code | NV | |
Document Quarterly Report | true | |
Entity Interactive Data Current | Yes | |
Local Phone Number | 961-1900 | |
Security Exchange Name | NASDAQ | |
Entity Address, City or Town | Boca Raton | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Entity Address, Address Line One | 6800 Broken Sound Parkway NW | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 33487 |
CONSOLIDATED BALANCE SHEETS (Un
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Current Assets: | ||
Cash | $ 182,846,301 | $ 161,613,077 |
Accounts receivable, net of allowance for doubtful accounts of $764,102 and $596,602, respectively | 18,383,012 | 11,063,821 |
Inventory | 7,494,440 | 3,267,670 |
Other current assets | 7,739,048 | 10,834,693 |
Total current assets | 216,462,801 | 186,779,261 |
Fixed assets, net | 1,432,137 | 472,683 |
Other Assets: | ||
License rights | 20,000,000 | 20,000,000 |
Intangible assets, net | 4,688,114 | 4,092,679 |
Other assets | 3,635,227 | 324,855 |
Security deposit | 334,866 | 314,446 |
Total other assets | 28,658,207 | 24,731,980 |
Total assets | 246,553,145 | 211,983,924 |
Current Liabilities: | ||
Accounts payable | 19,499,238 | 22,743,841 |
Other current liabilities | 22,376,617 | 18,334,948 |
Total current liabilities | 41,875,855 | 41,078,789 |
Long-Term Liabilities: | ||
Long-term debt | 194,095,220 | 73,381,014 |
Operating lease liability | 2,488,101 | |
Total liabilities | 238,459,176 | 114,459,803 |
Stockholders' Equity: | ||
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding | ||
Common stock - par value $0.001; 350,000,000 shares authorized: 241,221,840 and 240,462,439 issued and outstanding, respectively | 241,222 | 240,463 |
Additional paid-in capital | 621,871,919 | 616,559,938 |
Accumulated deficit | (614,019,172) | (519,276,280) |
Total stockholders' equity | 8,093,969 | 97,524,121 |
Total liabilities and stockholders' equity | $ 246,553,145 | $ 211,983,924 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts | $ 764,102 | $ 596,602 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, authorized | 10,000,000 | 10,000,000 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized | 350,000,000 | 350,000,000 |
Common stock, issued | 241,221,840 | 240,462,439 |
Common stock, outstanding | 241,221,840 | 240,462,439 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Statement [Abstract] | ||||
Revenues, net | $ 6,078,865 | $ 3,763,010 | $ 10,025,516 | $ 7,536,402 |
Cost of goods sold | 1,248,860 | 454,161 | 2,011,687 | 1,087,784 |
Gross profit | 4,830,005 | 3,308,849 | 8,013,829 | 6,448,618 |
Operating expenses: | ||||
Sales, general, and administrative | 41,387,451 | 29,466,770 | 76,251,533 | 50,224,007 |
Research and development | 4,964,368 | 6,798,380 | 11,282,250 | 13,837,677 |
Depreciation and amortization | 115,059 | 65,603 | 221,997 | 125,224 |
Total operating expenses | 46,466,878 | 36,330,753 | 87,755,780 | 64,186,908 |
Operating loss | (41,636,873) | (33,021,904) | (79,741,951) | (57,738,290) |
Other (expense) income | ||||
Gain (Loss) on Extinguishment of Debt | (10,057,632) | (10,057,632) | ||
Miscellaneous income | 486,597 | 334,238 | 1,175,318 | 648,795 |
Interest expense | (4,028,609) | (531,382) | (6,118,627) | (531,382) |
Total other (expense) income | (13,599,644) | (197,144) | (15,000,941) | 117,413 |
Loss before income taxes | (55,236,517) | (33,219,048) | (94,742,892) | (57,620,877) |
Net loss | $ (55,236,517) | $ (33,219,048) | $ (94,742,892) | $ (57,620,877) |
Loss per share, basic and diluted: | ||||
Net loss per share, basic and diluted (in dollars per share) | $ (0.23) | $ (0.15) | $ (0.39) | $ (0.27) |
Weighted average number of common shares outstanding, basic and diluted (in shares) | 241,221,840 | 216,640,186 | 241,114,532 | 216,583,067 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) | Common Stock | Additional Paid in Capital | Accumulated Deficit | Total |
Beginning balance at Dec. 31, 2017 | $ 216,430 | $ 516,351,405 | $ (386,659,120) | $ 129,908,715 |
Beginning balance (in shares) at Dec. 31, 2017 | 216,429,642 | |||
Shares issued for exercise of options, net | $ 154 | 43,902 | 44,056 | |
Shares issued for exercise of options, net (in shares) | 154,632 | |||
Share-based compensation | 1,751,358 | 1,751,358 | ||
Net loss | (24,401,829) | (24,401,829) | ||
Ending balance at Mar. 31, 2018 | $ 216,584 | 518,146,665 | (411,060,949) | 107,302,300 |
Ending balance (in shares) at Mar. 31, 2018 | 216,584,274 | |||
Beginning balance at Dec. 31, 2017 | $ 216,430 | 516,351,405 | (386,659,120) | 129,908,715 |
Beginning balance (in shares) at Dec. 31, 2017 | 216,429,642 | |||
Net loss | (57,620,877) | |||
Ending balance at Jun. 30, 2018 | $ 216,834 | 521,608,436 | (444,279,997) | 77,545,273 |
Ending balance (in shares) at Jun. 30, 2018 | 216,834,059 | |||
Beginning balance at Mar. 31, 2018 | $ 216,584 | 518,146,665 | (411,060,949) | 107,302,300 |
Beginning balance (in shares) at Mar. 31, 2018 | 216,584,274 | |||
Shares issued for exercise of options, net | $ 250 | 1,084,689 | 1,084,939 | |
Shares issued for exercise of options, net (in shares) | 249,785 | |||
Share-based compensation | 2,377,082 | 2,377,082 | ||
Net loss | (33,219,048) | (33,219,048) | ||
Ending balance at Jun. 30, 2018 | $ 216,834 | 521,608,436 | (444,279,997) | 77,545,273 |
Ending balance (in shares) at Jun. 30, 2018 | 216,834,059 | |||
Beginning balance at Dec. 31, 2018 | $ 240,463 | 616,559,938 | (519,276,280) | $ 97,524,121 |
Beginning balance (in shares) at Dec. 31, 2018 | 240,462,439 | 240,462,439 | ||
Shares issued for exercise of options and warrants, net | $ 759 | 99,348 | $ 100,107 | |
Shares issued for exercise of options and warrants, net (in shares) | 759,401 | |||
Share-based compensation | 2,575,369 | 2,575,369 | ||
Net loss | (39,506,375) | (39,506,375) | ||
Ending balance at Mar. 31, 2019 | $ 241,222 | 619,234,655 | (558,782,655) | 60,693,222 |
Ending balance (in shares) at Mar. 31, 2019 | 241,221,840 | |||
Beginning balance at Dec. 31, 2018 | $ 240,463 | 616,559,938 | (519,276,280) | $ 97,524,121 |
Beginning balance (in shares) at Dec. 31, 2018 | 240,462,439 | 240,462,439 | ||
Shares issued for exercise of options, net | $ 100,107 | |||
Net loss | (94,742,892) | |||
Ending balance at Jun. 30, 2019 | $ 241,222 | 621,871,919 | (614,019,172) | $ 8,093,969 |
Ending balance (in shares) at Jun. 30, 2019 | 241,221,840 | 241,221,840 | ||
Beginning balance at Mar. 31, 2019 | $ 241,222 | 619,234,655 | (558,782,655) | $ 60,693,222 |
Beginning balance (in shares) at Mar. 31, 2019 | 241,221,840 | |||
Share-based compensation | 2,637,264 | 2,637,264 | ||
Net loss | (55,236,517) | (55,236,517) | ||
Ending balance at Jun. 30, 2019 | $ 241,222 | $ 621,871,919 | $ (614,019,172) | $ 8,093,969 |
Ending balance (in shares) at Jun. 30, 2019 | 241,221,840 | 241,221,840 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss | $ (94,742,892) | $ (57,620,877) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation of fixed assets | 133,049 | 79,201 |
Loss on extinguishment of debt | 10,057,632 | |
Amortization of intangible assets | 88,948 | 46,023 |
Other Noncash Expense | 78,864 | |
Non-cash operating lease expense | 443,734 | |
Provision for doubtful accounts | 167,500 | 38,024 |
Share-based compensation | 5,224,212 | 4,128,440 |
Amortization of deferred financing costs | 316,880 | 30,155 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (7,486,691) | (1,335,209) |
Inventory | (4,226,770) | (395,219) |
Other current assets | 1,710,697 | 2,539,394 |
Accounts payable | (3,244,603) | 7,329,560 |
Accrued expenses and other liabilities | 2,801,717 | 561,615 |
Net cash used in operating activities | (88,677,723) | (44,598,893) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Patent costs | (763,247) | (434,677) |
Purchase of fixed assets | (1,092,504) | (45,720) |
Payment of security deposit | (20,420) | (11,486) |
Net cash used in investing activities | (1,876,171) | (491,883) |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds from exercise of options | 100,107 | 1,128,996 |
Repayments of Other Long-term Debt | (81,660,719) | |
Proceeds from Other Debt | 200,000,000 | 75,000,000 |
Payments of Financing Costs | (6,652,270) | (3,786,918) |
Net cash provided by financing activities | 111,787,118 | 72,342,078 |
Increase in cash | 21,233,224 | 27,251,302 |
Cash, beginning of period | 161,613,077 | 127,135,628 |
Cash, end of period | 182,846,301 | $ 154,386,930 |
Supplemental disclosure of cash flow information | ||
Interest paid | $ 6,989,570 |
THE COMPANY
THE COMPANY | 6 Months Ended |
Jun. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
THE COMPANY | NOTE 1 – THE COMPANY TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as “our company,” “we,” “our,” or “us.” Nature of Business We are a women’s healthcare company focused on creating and commercializing innovative products to support the lifespan of women and championing awareness of women’s healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled, long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD ® ® With our SYMBODA™ technology, we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our track record of commercialization allows us to efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products. During 2018 , U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our FDA-approved product, IMVEXXY® (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched BIJUVA®, our hormone therapy combination of bio-identical 17 ß-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus. We are also focused on commercialization activities necessary for launch of ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent unintended pregnancy for up to a full year, which was approved by the FDA on August 10, 2018. On July 30, 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. In addition, on July 30, 2018, we entered into an exclusive license agreement, or the Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. On June 6, 2019, we entered into an exclusive license and supply agreement with Theramex HQ UK Limited, or Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel. |
BASIS OF PRESENTATION AND RECEN
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS | 6 Months Ended |
Jun. 30, 2019 | |
Basis Of Presentation And Recently Issued Accounting Pronouncements | |
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS | NOTE 2 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Interim Financial Statements The accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated balance sheet as of December 31, 2018. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period in the future. Recently Issued Accounting Pronouncements In August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating the effect of this guidance on our disclosures. In June 2018, the FASB issued ASU 2018 -07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements. In February 2016, the FASB issued ASU 2016 -02 , Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. In July 2018, the FASB amended the new leases standard and issued ASU 2018 -11 , Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016 -02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018 -11 and we recorded a $3.8 million right of use asset and a $4.1 million liability related to adoption of this standard. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess ( 1 ) whether existing or expired contracts contain leases, ( 2 ) lease classification for any existing or expired leases, and ( 3 ) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Fair Value of Financial Instruments Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of June 30, 2019 (as disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2). We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements. Level 1 unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and Level 3 unobservable inputs for the asset or liability. At June 30, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company’s impairment test on an annual basis. Trade Accounts Receivable and Allowance for Doubtful Accounts Revenue Recognition We adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered “completed” if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation. Prescription Products As of June 30, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer’s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. In consignment arrangements, control of the product is transferred at the point in time when the goods are removed from consignment stock and sold to the end customer. We typically satisfy our performance obligations and recognize revenue at a point in time, generally when products are shipped to the customer, depending on the terms underlying each arrangement. In circumstances where our products are on consignment, revenue is generally recognized when the prescription is filled. Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer. The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract’s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known. We accept returns of unsalable prescription products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the customer’s consideration. Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Return estimates are recorded in the accrued expenses and other current liabilities on the consolidated balance sheet. We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized. As part of the commercial launch for IMVEXXY during the third quarter of 2018 and for BIJUVA in the second quarter of 2019, we introduced a co-pay assistance program where eligible enrolled patients do not pay more than $35 for prescription fills. This allows patients to access the product at a reasonable cost regardless of insurance coverage. We reimburse pharmacies for this discount through third-party vendors. We consider these payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients’ insurance. Payers may change coverage levels for IMVEXXY or BIJUVA positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of IMVEXXY and BIJUVA is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain revenue recognized for IMVEXXY and BIJUVA to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for IMVEXXY and BIJUVA is constrained by our estimates of the amount to be paid for the co-pay assistance program for IMVEXXY and BIJUVA which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate any constraint each reporting period. Disaggregation of revenue The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018: For the Three Months Ended June 30, For the Six Months 2019 2018 2019 2018 Prescription vitamins $ 2,822,872 $ 3,763,010 $ 4,758,844 $ 7,536,402 IMVEXXY 3,121,711 — 5,132,390 — BIJUVA 134,282 — 134,282 — Net revenue $ 6,078,865 $ 3,763,010 $ 10,025,516 $ 7,536,402 Share-Based Compensation We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee’s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees. Research and Development Expenses Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&D expenses include professional research and advice regarding R&D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known. Segment Reporting We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment. |
INVENTORY
INVENTORY | 6 Months Ended |
Jun. 30, 2019 | |
Inventory Disclosure [Abstract] | |
INVENTORY | NOTE 4 – INVENTORY Inventory consists of the following: June 30, December 31, Finished product $ 4,382,969 $ 2,908,958 Work in process 439,993 339,312 Raw material 2,671,478 19,400 TOTAL INVENTORY $ 7,494,440 $ 3,267,670 |
OTHER CURRENT ASSETS
OTHER CURRENT ASSETS | 6 Months Ended |
Jun. 30, 2019 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
OTHER CURRENT ASSETS | NOTE 5 – OTHER CURRENT ASSETS Other current assets consist of the following: June 30, December 31, Prepaid sales and marketing costs $ 2,568,100 $ 5,148,789 Deferred financing fees (Note 9) 550,757 1,898,074 Prepaid insurance 686,891 790,465 Other prepaid costs 3,933,300 2,997,365 TOTAL OTHER CURRENT ASSETS $ 7,739,048 $ 10,834,693 |
FIXED ASSETS, NET
FIXED ASSETS, NET | 6 Months Ended |
Jun. 30, 2019 | |
Property, Plant and Equipment [Abstract] | |
FIXED ASSETS, NET | NOTE 6 – FIXED ASSETS, NET Fixed assets, net consist of the following: June 30, December 31, Accounting system $ 301,096 $ 301,096 Equipment 581,150 490,576 Furniture and fixtures 940,963 116,542 Computer hardware 220,820 80,211 Leasehold improvements 74,788 37,888 2,118,817 1,026,313 Accumulated depreciation (686,680 ) (553,630 ) TOTAL FIXED ASSETS, NET $ 1,432,137 $ 472,683 Depreciation expense for the three months ended June 30, 2019 and 2018 was $66,556 and $40,777 , respectively, and for the six months ended June 30, 2019 and 2018 was $133,049 and $79,201 , respectively. |
INTANGIBLE ASSETS
INTANGIBLE ASSETS | 6 Months Ended |
Jun. 30, 2019 | |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | |
INTANGIBLE ASSETS | NOTE 7 – INTANGIBLE ASSETS The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2019 and December 31, 2018: June 30, 2019 Gross Carrying Amount Accumulated Amortization Net Weighted-Average Amortizable intangible assets: Approved hormone therapy drug candidate patents 2,962,563 (370,338 ) 2,592,225 13.5 Hormone therapy drug candidate patents (pending) 1,833,584 — 1,833,584 n/a Non-amortizable intangible assets: Multiple trademarks 262,305 — 262,305 indefinite TOTAL $ 5,058,452 $ (370,338 ) $ 4,688,114 December 31, 2018 Gross Carrying Amount Accumulated Amortization Net Weighted-Average Amortizable intangible assets: OPERA ® $ 31,951 $ (10,484 ) $ 21,467 10.75 Development costs of corporate website 91,743 (91,743 ) — n/a Approved hormone therapy drug candidate patents 2,234,129 (282,485 ) 1,951,644 14 Hormone therapy drug candidate patents (pending) 1,855,279 — 1,855,279 n/a Non-amortizable intangible assets: Multiple trademarks 264,289 — 264,289 indefinite TOTAL $ 4,477,391 $ (384,712 ) $ 4,092,679 We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the six months ended June 30, 2019, we wrote off $78,864 in costs related to trademarks and patents, including the net carrying amount of the OPERA patent. As of June 30, 2019, we had 26 issued domestic, or U.S., patents and 27 issued foreign patents, including: ● 12 domestic patents and five foreign patents that relate to BIJUVA as well as three domestic patents that relate to non-approved doses of BIJUVA. These patents establish an important intellectual property foundation for BIJUVA and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; ● Four foreign patents that relate to our progesterone-only candidate, which are owned by us. The foreign patents will expire no earlier than 2033. In addition, we have pending patent applications with respect to our progesterone-only candidate in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; ● Five domestic patents (three utility and two design) and 13 foreign patents (three utility and ten design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain jurisdictions, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea; ● One domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; ● One domestic utility patent and five foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Australia, Brazil, Canada, Europe, Mexico, Japan, and South Africa; ● One domestic utility patent that relates to a product candidate containing d-limonene, which is owned by us and will expire in 2036; ● One domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031; and ● Two domestic utilitypatents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea. Amortization expense was $48,503 and $24,826 for the three months ended June 30, 2019 and 2018, respectively and $88,948 and $46,023 for the six months ended June 30, 2019 and 2018, respectively. Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: Year Ending December 31, Estimated Amortization 2019(6 months) $ 96,008 2020 $ 196,017 2021 $ 196,017 2022 $ 196,017 2023 $ 196,017 License Agreement with the Population Council On July 30, 2018, we entered into the Council License Agreement to commercialize in the U.S. ANNOVERA. We currently estimate that ANNOVERA will be commercially available as early as the third quarter of 2019 with a planned full commercial launch by the first quarter of 2020. Under the terms of the Council License Agreement, we paid the Population Council a milestone payment of $20,000,000 within 30 days following approval by the FDA of the NDA for ANNOVERA and will be required to pay the Population Council $20,000,000 within 30 days following the release of the first commercial batch of ANNOVERA. The Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We will assume responsibility for marketing expenses related to the commercialization of ANNOVERA. The milestone payment of $20,000,000 upon the FDA’s approval of ANNOVERA in the third quarter of 2018 was recorded as a finite-lived intangible asset in the consolidated balance sheet and will be amortized on a straight-line basis once it becomes available for use which is expected to be upon release of first commercial batch of ANNOVERA. In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $50,000,000 , a royalty of 5 % of net sales; (ii) for annual net sales greater than $50,000,000 and less than or equal to $150,000,000 , a royalty of 10 % of such net sales; and (iii) for net sales greater than $150,000,000 , a royalty of 15 % of such net sales. The annual royalty rate will be reduced to 50 % of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to 20 % of the initial rate. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20,000,000, half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement. We and the Population Council have agreed to form a joint product committee responsible for overseeing activities under the Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee. The Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population Council. We assess our intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. If impairment indicators are present or changes in circumstance suggest that impairment may exist, we perform a recoverability test by comparing the sum of the estimated undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, we would determine the fair value of the intangible asset and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset’s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life. License Agreement with Knight Therapeutics Inc. On July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased3,921,568 shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock at a price of $5.10 , for proceeds of $20,000,000 , on August 6, 2018. License Agreement with Theramex On June 6, 2019, we entered into an exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR14 million in cash as an upfront fee on August 5, 2019. Within thirty days of signing License Agreement, we are required to provide Theramex the regulatory materials and clinical data that are necessary for Theramex to obtain marketing authorizations and other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. The revenue related to fees received by us will be recognized once our performance obligations have been satisfied. We are eligible to receive additional milestone payments comprised of (i) up to an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii) up to an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR 25 million to EUR100 million. We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. |
OTHER CURRENT LIABILITIES
OTHER CURRENT LIABILITIES | 6 Months Ended |
Jun. 30, 2019 | |
Payables and Accruals [Abstract] | |
OTHER CURRENT LIABILITIES | NOTE 8 – OTHER CURRENT LIABILITIES Other current liabilities consist of the following: June 30, December 31, Accrued payroll, bonuses and commission costs $ 5,115,082 $ 6,854,002 Allowance for coupons and returns 6,340,450 5,294,120 Accrued sales and marketing costs 2,107,696 2,288,028 Accrued compensated absences 1,492,131 1,178,110 Allowance for wholesale distributor fees 2,077,444 792,891 Accrued legal and accounting expense 367,898 385,824 Accrued research and development 1,402,600 388,675 Operating lease liability 1,187,029 — Accrued rent — 365,155 Accrued rebates 2,251,047 412,570 Other accrued expenses 35,240 375,573 TOTAL OTHER CURRENT LIABILITIES $ 22,376,617 $ 18,334,948 |
DEBT
DEBT | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
DEBT | NOTE 9 – DEBT On April 24, 2019, we entered into a Financing Agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of the Company’s subsidiaries party thereto from time to time as guarantors, which provides us with a $300,000,000 first lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i) $200,000,000 was drawn upon entering into the Financing Agreement; (ii) $50,000,000 will be available to us upon the designation of our ANNOVERA product as a new category of birth control by the FDA on or prior to December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $50,000,000 will be available to us upon our achieving $11,000,000 in net revenues, as defined in the Financing Agreement, from our IMVEXXY, BIJUVA and ANNOVERA products for the fourth quarter of 2019 and satisfaction (or waiver) of other customary conditions precedent. Borrowings under the Facility accrue interest at either (i)3-month LIBOR plus7.75%, subject to a LIBOR floor of 2.70% or (ii) the prime rate plus6.75%, subject to a prime rate floor of 5.20%, as selected by us. Interest on amounts borrowed under the Facility will be payable quarterly. The outstanding principal amount of the Facility is payable in four equal quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i)30.0% for the first two years following the initial funding date of the applicable borrowing, (ii)5.0% for the third year following the initial funding date of the applicable borrowing, (iii)3.0% for the fourth year following the initial funding date of the applicable borrowing and (iv)1.0% for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to 2.5% of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i) maintain a minimum unrestricted cash balance of $50,000,000, which will increase to $60,000,000 if we draw either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. The Financing Agreement also includes other representations, warranties, indemnities and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all existing and after-acquired assets of our company and its subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions. On May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $200,000,000, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in three separate tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate equal to the sum of (i) one-month LIBOR (subject to a LIBOR floor of1.50%) plus (ii)7.75% per annum. On April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $81,661,000 was used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of 4%, a repayment fee of 4% and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit Agreement, we recorded $10,057,632 in loss on extinguishment of debt in the accompanying unaudited consolidated financial statements. Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the six months ending June 30, 2019 related to the Credit Agreement was $1,816,747. During the six months ended June 30, 2019, and prior to the repayment of the Credit Agreement, we amortized $120,146 of deferred financing fees as interest expense in the accompanying unaudited consolidated financial statements. As of June 30, 2019, we had $200,000,000 in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying unaudited consolidated financial statements. We incurred $6,652,270 in deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement have been allocated pro rata between the funded and unfunded portions of each tranche. Allocated deferred financing fees related to Tranche 1 of $6,101,513 have been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred financing fees associated with unfunded tranches were deferred as assets until the Tranche 2 and Tranche 3 milestones have been met. As of June 30, 2019, deferred financing fees related to Tranche 2 and Tranche 3 were included in other current assets in the accompanying consolidated financial statements. During both the three and six months ended June 30, 2019, we amortized $196,734 of deferred financing fees related to Tranche 1 as interest expense in the accompanying unaudited consolidated financial statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears. Interest expense for both the three and six months ending June 30, 2019 was $3,985,000. The overall effective interest rate under the Financing Agreement was approximately 11% as of June 30, 2019. As of June 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: June 30, December 31, Financing Agreement $ 200,000,000 $ — Credit Agreement — 75,000,000 Debt discount and financing fees (5,904,780 ) (1,618,986 ) TOTAL LONG-TERM DEBT $ 194,095,220 $ 73,381,014 |
NET LOSS PER SHARE
NET LOSS PER SHARE | 6 Months Ended |
Jun. 30, 2019 | |
Loss per share, basic and diluted: | |
NET LOSS PER SHARE | NOTE 10– NET LOSS PER SHARE We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been antidilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. Three and Six months ended June 30, 2019 June 30, 2018 Stock options 22,072,469 25,210,899 Warrants 1,832,571 3,007,571 Restricted stock awards 1,040,000 — TOTAL 24,945,040 28,218,470 |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 6 Months Ended |
Jun. 30, 2019 | |
Stockholders' Equity: | |
STOCKHOLDERS' EQUITY | NOTE 11 – STOCKHOLDERS’ EQUITY Preferred Stock At June 30, 2019, we had 10,000,000 shares of preferred stock, par value $0.001 per share, authorized for issuance, of which no shares of preferred stock were issued or outstanding. Common Stock At June 30, 2019, we had 350,000,000 shares of Common Stock authorized for issuance, of which 241,221,840 shares of Common Stock were issued and outstanding. Issuances During the Three and Six Months Ended June 30, 2019 During the three months ended June 30, 2019, no options to purchase shares of Common Stock were exercised. During the six months ended June 30, 2019, certain individuals exercised stock options to purchase 276,383 shares of Common Stock for $100,107 in cash. Also, during the same period, stock options to purchase 12,097 shares of Common Stock were exercised pursuant to the options’ cashless exercise provisions, wherein 11,834 shares of Common Stock were issued. Issuances During the Three and Six Months Ended June 30, 2018 During the three months ended June 30, 2018, certain individuals exercised stock options to purchase 249,785 shares of Common Stock for $1,084,939 in cash. During the six months ended June 30, 2018, certain individuals exercised stock options to purchase 394,576 shares of Common Stock for $1,128,996 in cash. Also, during the six months ended June 30, 2018, stock options to purchase 10,000 shares of Common Stock were exercised pursuant to the options’ cashless exercise provisions, wherein 9,841 shares of Common Stock were issued. Warrants to Purchase Common Stock As of June 30, 2019, we had warrants outstanding to purchase an aggregate of 1,832,571 shares of Common Stock with a weighted-average contractual remaining life of approximately 2.5 years, and exercise prices ranging from $0.24 to $8.20 per share, resulting in a weighted average exercise price of $2.62 per share. The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend rate and the term of the warrant. During the six months ended June 30, 2019, we granted warrants to purchase75,000 shares of Common Stock to outside consultants at an exercise price of $5.63 . The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of 5 years; volatility of 60.8 %; risk free rate of 2.52 %; and dividend yield of 0 %. The grant date fair value of the warrants was $3.00 per share. The warrants are vesting ratably over a 12-month period and have an expiration date of February 12, 2024. During the six months ended June 30, 2018, we granted warrants to purchase175,000 shares of Common Stock to outside consultants at an exercise price of $5.16 . The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of 5 years; volatility of 62.1 %; risk free rate of 2.36 %; and dividend yield of 0 %. The grant date fair value of the warrants was $2.79 per share. The warrants vest ratably over a 12-month period and have an expiration date of March 15, 2023. During the three months ended June 30, 2019 and 2018, we recorded $56,172 and $164,840 , respectively, and during the six months ended June 30, 2019 and 2018, we recorded $141,888 and $256,315 , respectively, as share based compensation expense in the accompanying consolidated financial statements related to warrants. As of June 30, 2019, total unrecognized estimated compensation expense related to the unvested portion of these warrants was approximately $139,000 , which is expected to be recognized over a weighted-average period of0.6 years. During the six months ended June 30, 2019, warrants to purchase 1,250,000 shares of Common Stock were exercised pursuant to the options’ cashless exercise provisions, wherein 471,184 shares of Common Stock were issued. During the six months ended June 30, 2018, no warrants were exercised. Options to Purchase Common Stock In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were non-qualified stock options to purchase 15,116,995 shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009 Plan. In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were non-qualified stock options to purchase 6,317,974 shares of Common Stock outstanding and 1,040,000 restricted stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan on June 20, 2019, no future awards may be made under the 2012 Plan. On June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were16,812,383 shares of Common Stock authorized for issuance thereunder, consisting of (i)14,362,500 new shares, (ii)2,393,833 unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding “Awards” (as defined in the 2012 Plan), and (iii)56,050 unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding “Awards” (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity “Awards” under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of June 30, 2019, there were non-qualified stock options to purchase 637,500 shares of Common Stock outstanding under the 2019 Plan. The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model for options granted during the six months ended June 30, 2019 and 2018 are set forth in the table below. Six months ended June 30, 2019 2018 Risk-free interest rate 2.19—2.54 % 2.38—2.63 % Volatility 61.25—61.85 % 61.82—64.04 % Term (in years) 5.5—6.25 5.1—6.25 Dividend yield 0.00% 0.00% A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: Number of Shares Underlying Stock Options Weighted Average Exercise Price Weighted Aggregate Intrinsic Value Balance at December 31, 2018 20,872,824 $ 4.93 5.94 $ 12,239,876 Granted 1,544,500 $ 4.40 Exercised (288,480 ) $ 0.35 $ 1,315,238 Expired/Forfeited (56,375 ) $ 5.77 Balance at June 30, 2019 22,072,469 $ 4.95 5.80 $ 3,945,665 Vested and Exercisable at June 30, 2019 17,125,888 $ 4.79 4.94 $ 3,945,665 Unvested at June 30, 2019 4,946,581 $ 5.48 8.79 $ 0 At June 30, 2019, our outstanding stock options had exercise prices ranging from $0.10 to $8.92 per share. The weighted average grant date fair value per share of options granted was $2.57 and $3.15 during the six months ended June 30, 2019 and 2018, respectively. Share-based compensation expense for options recognized in our results of operations for the three months ended June 30, 2019 and 2018 ($2,230,829 and $2,212,241 , respectively) and for the six months ended June 30, 2019 and 2018 ($4,374,069 and $3,872,125 , respectively) is based on vested awards. At June 30, 2019, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $11,606,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of2.1 years. No tax benefit was realized due to a continued pattern of operating losses. Restricted Stock Restricted stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited. On December 13, 2018, we granted 1,040,000 restricted stock units to certain executive employees which will vest at the end of the third year. The grant date fair value was $4.06 per unit. During the three and six months ended June 30, 2019 we recorded $350,263 and $696,676 , respectively, in share-based compensation expense related to restricted stock units. At June 30, 2019, total unrecognized estimated compensation expense related to unvested restricted stock units was approximately $3,453,000 , which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 2.5 years. At June 30, 2019,1,040,000 restricted stock awards remained outstanding. Cash-Settled Stock Appreciation Rights (SARs) On July 1, 2018, we issued cash-settled SARs to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30, 2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over the grant price is paid in cash and not in Common Stock. Cash settled SARs were recorded in our consolidated balance sheets as a liability until the date of exercise. The fair value of each SAR award was estimated using the Black-Scholes valuation model. In accordance with ASC Topic 718, “Stock Compensation,” the fair value of each SAR award was recalculated at the end of each reporting period and the liability and expense adjusted based on the new fair value and the percent vested. At June 30, 2019, the fair market value of our Common Stock was lower than the grant price of SARs and, as a result, the recorded liability was reversed and no cash payment was made. |
INCOME TAXES
INCOME TAXES | 6 Months Ended |
Jun. 30, 2019 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | NOTE 12 – INCOME TAXES Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2019 as a result of (i) the losses recorded during the six months ended June 30, 2019, (ii) additional losses expected for the remainder of 2019, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2019, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period. |
RELATED PARTIES
RELATED PARTIES | 6 Months Ended |
Jun. 30, 2019 | |
Related Party Transactions [Abstract] | |
RELATED PARTIES | NOTE 13 – RELATED PARTIES In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of our company since July 2015. During the three months ended June 30, 2019 and 2018, we were billed by Catalent approximately $ 974,000 and $ 1,266,000 , respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. During the six months ended June 30, 2019 and 2018, we were billed by Catalent approximately $ 2,371,000 and $ 2,040,000 , respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of June 30, 2019 and December 31, 2018, there were amounts due to Catalent of approximately $ 243,000 and $ 88,000 , respectively. |
BUSINESS CONCENTRATIONS
BUSINESS CONCENTRATIONS | 6 Months Ended |
Jun. 30, 2019 | |
Risks and Uncertainties [Abstract] | |
BUSINESS CONCENTRATIONS | NOTE 14 – BUSINESS CONCENTRATIONS We purchase our prescription products from several suppliers with approximately 14%,18%,31% and37% of our purchases were supplied by four vendors each, respectively, during the six months ended June 30, 2019 and approximately 100% of our purchases were supplied from one vendor for the six months ended June 30, 2018. We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the six months ended June 30, 2019, three customers each generated more than 10% of our total revenues. During the six months ended June 30, 2018, four customers each generated more than 10% of our total revenues. Revenue generated from the three customers combined accounted for approximately 60% of our recognized revenue for the six months ended June 30, 2019 and revenue generated from the four customers combined accounted for approximately71% of our recognized revenue for the six months ended June 30, 2018. During the six months ended June 30, 2019, Pillpack, Inc. accounted for approximately $3,615,000of our revenue, AmerisourceBergen accounted for approximately $1,365,000of our revenue and Cardinal Health accounted for approximately $1,048,000of our revenue. During the six months ended June 30, 2018, PI Services generated approximately $981,000of our revenue, Pillpack, Inc. generated approximately $2,088,000of our revenue, AmerisourceBergen generated approximately $1,283,000of our revenue and Cardinal Health generated approximately $971,000of our revenue. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 6 Months Ended |
Jun. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 15 – COMMITMENTS AND CONTINGENCIES We adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used to conduct our business. Upon adoption, we have recognized a right-of-use asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016. In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes 56,212 rentable square feet, or the full premises, of which lease on 7,561 square feet commenced in 2018 and the lease on the remaining 48,651 square feet will commence sometime in the third quarter of 2019, or the full premises commencement date. The lease will expire 11 years after full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In addition, we will be entitled to reimbursement from the landlord of up to $1,800,000 for tenant improvements. In June 2019, we entered into an agreement with the same lessors to lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the fourth quarter of 2019. Supplemental lease information as of June 30, 2019 Right-of-use asset (included in Other assets) $ 3,316,436 Short-term operating lease liability (included in Other current liabilities) $ 1,187,029 Long-term operating lease liability $ 2,488,101 Weighted average remaining term 5Years Weighted average discount rate 8.25 % Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities for operating lease $ 564,092 Right-of-use assets obtained in exchange for lease obligation $ 3,760,171 The following table reconciles the undiscounted cash flows for all operating leases at June 30, 2019 to the operating lease liabilities recorded on the balance sheet: Years Ending December 31, 2019 (6 months) $ 595,649 2020 1,292,914 2021 1,135,467 2022 172,651 2023 176,968 Thereafter 1,228,504 Total undiscounted lease payments 4,602,153 Less: imputed interest (927,023 ) Present value of lease payments $ 3,675,130 As of June 30, 2019, we estimated undiscounted fixed future minimum rental commitments of approximately $13,300,000 and estimated undiscounted variable future minimum rental commitments of approximately $6,400,000 over the term of the lease related to the operating lease for the new corporate office that we entered into in October 2018 and an additional suite that we entered into in 2019 that had not commenced yet, as disclosed above. During the three and six months ended June 30, 2019, operating lease expense related to our real estate leases was approximately $295,000 and $590,000 , respectively, and variable lease expense was insignificant for the three and six months ended June 30, 2019. Rent expense totaled $257,000 and $515,000 during the three and six months ended June 30, 2018, respectively. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of June 30, 2019 (as disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2). We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements. Level 1 unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and Level 3 unobservable inputs for the asset or liability. At June 30, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company’s impairment test on an annual basis. |
Trade Accounts Receivable and Allowance for Doubtful Accounts | Trade Accounts Receivable and Allowance for Doubtful Accounts |
Revenue Recognition | Revenue Recognition We adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered “completed” if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation. Prescription Products As of June 30, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer’s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. In consignment arrangements, control of the product is transferred at the point in time when the goods are removed from consignment stock and sold to the end customer. We typically satisfy our performance obligations and recognize revenue at a point in time, generally when products are shipped to the customer, depending on the terms underlying each arrangement. In circumstances where our products are on consignment, revenue is generally recognized when the prescription is filled. Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer. The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract’s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known. We accept returns of unsalable prescription products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the customer’s consideration. Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Return estimates are recorded in the accrued expenses and other current liabilities on the consolidated balance sheet. We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized. As part of the commercial launch for IMVEXXY during the third quarter of 2018 and for BIJUVA in the second quarter of 2019, we introduced a co-pay assistance program where eligible enrolled patients do not pay more than $35 for prescription fills. This allows patients to access the product at a reasonable cost regardless of insurance coverage. We reimburse pharmacies for this discount through third-party vendors. We consider these payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients’ insurance. Payers may change coverage levels for IMVEXXY or BIJUVA positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of IMVEXXY and BIJUVA is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain revenue recognized for IMVEXXY and BIJUVA to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for IMVEXXY and BIJUVA is constrained by our estimates of the amount to be paid for the co-pay assistance program for IMVEXXY and BIJUVA which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate any constraint each reporting period. Disaggregation of revenue The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018: For the Three Months Ended June 30, For the Six Months 2019 2018 2019 2018 Prescription vitamins $ 2,822,872 $ 3,763,010 $ 4,758,844 $ 7,536,402 IMVEXXY 3,121,711 — 5,132,390 — BIJUVA 134,282 — 134,282 — Net revenue $ 6,078,865 $ 3,763,010 $ 10,025,516 $ 7,536,402 |
Share-Based Compensation | Share-Based Compensation We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee’s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees. |
Research and Development Expenses | Research and Development Expenses Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&D expenses include professional research and advice regarding R&D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known. |
Segment Reporting | Segment Reporting We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Schedule of disaggregated revenue | The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018: For the Three Months Ended June 30, For the Six Months 2019 2018 2019 2018 Prescription vitamins $ 2,822,872 $ 3,763,010 $ 4,758,844 $ 7,536,402 IMVEXXY 3,121,711 — 5,132,390 — BIJUVA 134,282 — 134,282 — Net revenue $ 6,078,865 $ 3,763,010 $ 10,025,516 $ 7,536,402 |
INVENTORY (Tables)
INVENTORY (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Inventory Disclosure [Abstract] | |
Schedule of inventory | Inventory consists of the following: June 30, December 31, Finished product $ 4,382,969 $ 2,908,958 Work in process 439,993 339,312 Raw material 2,671,478 19,400 TOTAL INVENTORY $ 7,494,440 $ 3,267,670 |
OTHER CURRENT ASSETS (Tables)
OTHER CURRENT ASSETS (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of other current assets | Other current assets consist of the following: June 30, December 31, Prepaid sales and marketing costs $ 2,568,100 $ 5,148,789 Deferred financing fees (Note 9) 550,757 1,898,074 Prepaid insurance 686,891 790,465 Other prepaid costs 3,933,300 2,997,365 TOTAL OTHER CURRENT ASSETS $ 7,739,048 $ 10,834,693 |
FIXED ASSETS, NET (Tables)
FIXED ASSETS, NET (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Property, Plant and Equipment [Abstract] | |
Schedule of fixed assets | Fixed assets, net consist of the following: June 30, December 31, Accounting system $ 301,096 $ 301,096 Equipment 581,150 490,576 Furniture and fixtures 940,963 116,542 Computer hardware 220,820 80,211 Leasehold improvements 74,788 37,888 2,118,817 1,026,313 Accumulated depreciation (686,680 ) (553,630 ) TOTAL FIXED ASSETS, NET $ 1,432,137 $ 472,683 |
INTANGIBLE ASSETS (Tables)
INTANGIBLE ASSETS (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | |
Schedule of intangible assets | The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2019 and December 31, 2018: June 30, 2019 Gross Carrying Amount Accumulated Amortization Net Weighted-Average Amortizable intangible assets: Approved hormone therapy drug candidate patents 2,962,563 (370,338 ) 2,592,225 13.5 Hormone therapy drug candidate patents (pending) 1,833,584 — 1,833,584 n/a Non-amortizable intangible assets: Multiple trademarks 262,305 — 262,305 indefinite TOTAL $ 5,058,452 $ (370,338 ) $ 4,688,114 December 31, 2018 Gross Carrying Amount Accumulated Amortization Net Weighted-Average Amortizable intangible assets: OPERA ® $ 31,951 $ (10,484 ) $ 21,467 10.75 Development costs of corporate website 91,743 (91,743 ) — n/a Approved hormone therapy drug candidate patents 2,234,129 (282,485 ) 1,951,644 14 Hormone therapy drug candidate patents (pending) 1,855,279 — 1,855,279 n/a Non-amortizable intangible assets: Multiple trademarks 264,289 — 264,289 indefinite TOTAL $ 4,477,391 $ (384,712 ) $ 4,092,679 |
Schedule of estimated amortization expense | Year Ending December 31, Estimated Amortization 2019(6 months) $ 96,008 2020 $ 196,017 2021 $ 196,017 2022 $ 196,017 2023 $ 196,017 |
OTHER CURRENT LIABILITIES (Tabl
OTHER CURRENT LIABILITIES (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Payables and Accruals [Abstract] | |
Other Current Liabilities [Table Text Block] | Other current liabilities consist of the following: June 30, December 31, Accrued payroll, bonuses and commission costs $ 5,115,082 $ 6,854,002 Allowance for coupons and returns 6,340,450 5,294,120 Accrued sales and marketing costs 2,107,696 2,288,028 Accrued compensated absences 1,492,131 1,178,110 Allowance for wholesale distributor fees 2,077,444 792,891 Accrued legal and accounting expense 367,898 385,824 Accrued research and development 1,402,600 388,675 Operating lease liability 1,187,029 — Accrued rent — 365,155 Accrued rebates 2,251,047 412,570 Other accrued expenses 35,240 375,573 TOTAL OTHER CURRENT LIABILITIES $ 22,376,617 $ 18,334,948 |
DEBT (Tables)
DEBT (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
Schedule of debt | June 30, December 31, Financing Agreement $ 200,000,000 $ — Credit Agreement — 75,000,000 Debt discount and financing fees (5,904,780 ) (1,618,986 ) TOTAL LONG-TERM DEBT $ 194,095,220 $ 73,381,014 |
NET LOSS PER SHARE (Tables)
NET LOSS PER SHARE (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Loss per share, basic and diluted: | |
Schedule of potentially dilutive securities | Three and Six months ended June 30, 2019 June 30, 2018 Stock options 22,072,469 25,210,899 Warrants 1,832,571 3,007,571 Restricted stock awards 1,040,000 — TOTAL 24,945,040 28,218,470 |
STOCKHOLDERS' EQUITY (Tables)
STOCKHOLDERS' EQUITY (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Stockholders' Equity: | |
Schedule of assumptions used in the Black-Scholes Model of stock options | Six months ended June 30, 2019 2018 Risk-free interest rate 2.19—2.54 % 2.38—2.63 % Volatility 61.25—61.85 % 61.82—64.04 % Term (in years) 5.5—6.25 5.1—6.25 Dividend yield 0.00% 0.00% |
Schedule of activity of 2009 and 2012 Plans | A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: Number of Shares Underlying Stock Options Weighted Average Exercise Price Weighted Aggregate Intrinsic Value Balance at December 31, 2018 20,872,824 $ 4.93 5.94 $ 12,239,876 Granted 1,544,500 $ 4.40 Exercised (288,480 ) $ 0.35 $ 1,315,238 Expired/Forfeited (56,375 ) $ 5.77 Balance at June 30, 2019 22,072,469 $ 4.95 5.80 $ 3,945,665 Vested and Exercisable at June 30, 2019 17,125,888 $ 4.79 4.94 $ 3,945,665 Unvested at June 30, 2019 4,946,581 $ 5.48 8.79 $ 0 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of supplemental lease information and cash flow information | Supplemental lease information as of June 30, 2019 Right-of-use asset (included in Other assets) $ 3,316,436 Short-term operating lease liability (included in Other current liabilities) $ 1,187,029 Long-term operating lease liability $ 2,488,101 Weighted average remaining term 5Years Weighted average discount rate 8.25 % Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities for operating lease $ 564,092 Right-of-use assets obtained in exchange for lease obligation $ 3,760,171 |
Reconciliation of undiscounted cash flows for all operating leases to the operating lease liabilities | The following table reconciles the undiscounted cash flows for all operating leases at June 30, 2019 to the operating lease liabilities recorded on the balance sheet: Years Ending December 31, 2019 (6 months) $ 595,649 2020 1,292,914 2021 1,135,467 2022 172,651 2023 176,968 Thereafter 1,228,504 Total undiscounted lease payments 4,602,153 Less: imputed interest (927,023 ) Present value of lease payments $ 3,675,130 |
THE COMPANY (Details)
THE COMPANY (Details) | Jun. 30, 2019 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Number of Subsidiares | 3 |
BASIS OF PRESENTATION AND REC_2
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) - USD ($) | Jun. 30, 2019 | Jan. 01, 2019 |
Right of use asset | $ 3,316,436 | $ 3,800,000 |
Lease liability | $ 3,675,130 | $ 4,100,000 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Revenues, net | $ 6,078,865 | $ 3,763,010 | $ 10,025,516 | $ 7,536,402 |
BIJUVA [Member] | ||||
Revenues, net | 134,282 | 134,282 | ||
Prescription Vitamins [Member] | ||||
Revenues, net | 2,822,872 | $ 3,763,010 | 4,758,844 | $ 7,536,402 |
IMVEXXY [Member] | ||||
Revenues, net | $ 3,121,711 | $ 5,132,390 |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) | 6 Months Ended |
Jun. 30, 2019USD ($) | |
Shelf life of prescription products following product expiration | 24 months |
Enrolled patients | $ 35 |
Minimum [Member] | |
Return period of unsalable prescription products | 6 months |
Maximum [Member] | |
Return period of unsalable prescription products | 12 months |
INVENTORY (Details)
INVENTORY (Details) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Inventory | ||
Finished product | $ 4,382,969 | $ 2,908,958 |
Work in process | 439,993 | 339,312 |
Raw material | 2,671,478 | 19,400 |
TOTAL INVENTORY | $ 7,494,440 | $ 3,267,670 |
OTHER CURRENT ASSETS (Details)
OTHER CURRENT ASSETS (Details) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Other Current Assets | ||
Prepaid sales and marketing costs | $ 2,568,100 | $ 5,148,789 |
Debt financing fees (Note 9) | 550,757 | 1,898,074 |
Prepaid insurance | 686,891 | 790,465 |
Other prepaid costs | 3,933,300 | 2,997,365 |
TOTAL OTHER CURRENT ASSETS | $ 7,739,048 | $ 10,834,693 |
FIXED ASSETS, NET (Details)
FIXED ASSETS, NET (Details) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Property, Plant and Equipment [Line Items] | ||
TOTAL FIXED ASSETS, GROSS | $ 2,118,817 | $ 1,026,313 |
Accumulated depreciation | (686,680) | (553,630) |
TOTAL FIXED ASSETS, NET | 1,432,137 | 472,683 |
Acounting System [Member] | ||
Property, Plant and Equipment [Line Items] | ||
TOTAL FIXED ASSETS, GROSS | 301,096 | 301,096,000 |
Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
TOTAL FIXED ASSETS, GROSS | 581,150 | 490,576 |
Furniture And Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
TOTAL FIXED ASSETS, GROSS | 940,963 | 116,542 |
Computer hardware [Member] | ||
Property, Plant and Equipment [Line Items] | ||
TOTAL FIXED ASSETS, GROSS | 220,820 | 80,211 |
Leasehold improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
TOTAL FIXED ASSETS, GROSS | $ 74,788 | $ 37,888 |
FIXED ASSETS, NET (Details Narr
FIXED ASSETS, NET (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation expense | $ 66,556 | $ 40,777 | $ 133,049 | $ 79,201 |
INTANGIBLE ASSETS (Details)
INTANGIBLE ASSETS (Details) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Finite-Lived Intangible Assets | ||
Accumulated Amortization | $ (370,338) | $ (384,712) |
Indefinite-Lived Intangible Assets | ||
Gross Carrying Amount | 5,058,452 | 4,477,391 |
Net Amount | 4,688,114 | 4,092,679 |
Hormone Therapy Drug Candidate Patents - (Pending) [Member] | ||
Finite-Lived Intangible Assets | ||
Gross Carrying Amount | 1,855,279 | |
Net Amount | 1,833,584 | 1,855,279 |
Multiple Trademarks [Member] | ||
Indefinite-Lived Intangible Assets | ||
Gross Carrying Amount | $ 262,305 | 264,289 |
Net Amount | 264,289 | |
Domestic Utilty Patent - Opera Software [Member] | ||
Finite-Lived Intangible Assets | ||
Gross Carrying Amount | 31,951 | |
Accumulated Amortization | (10,484) | |
Net Amount | $ 21,467 | |
Weighted average remaining amortization period | 13 years 6 months | 10 years 9 months |
Approved Hormone Therapy Drug Candidate Patents [Member] | ||
Finite-Lived Intangible Assets | ||
Gross Carrying Amount | $ 2,962,563 | $ 2,234,129 |
Accumulated Amortization | (370,338) | (282,485) |
Net Amount | $ 2,592,225 | $ 1,951,644 |
Weighted average remaining amortization period | 14 years | |
Development Costs Of Corporate Website [Member] | ||
Finite-Lived Intangible Assets | ||
Gross Carrying Amount | $ 91,743 | |
Accumulated Amortization | $ (91,743) |
INTANGIBLE ASSETS (Details 1)
INTANGIBLE ASSETS (Details 1) | Jun. 30, 2019USD ($) |
Year Ending December 31, | |
2019 (9 months) | $ 96,008 |
2020 | 196,017 |
2021 | 196,017 |
2022 | 196,017 |
2023 | $ 196,017 |
INTANGIBLE ASSETS (Details Narr
INTANGIBLE ASSETS (Details Narrative) $ / shares in Units, € in Millions | Aug. 06, 2018USD ($)$ / sharesshares | Jul. 30, 2018USD ($) | Jun. 30, 2019USD ($) | Mar. 31, 2019USD ($) | Jun. 30, 2018USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | Jun. 30, 2019EUR (€) | Jun. 30, 2019USD ($) |
Finite-Lived Intangible Assets [Line Items] | |||||||||
Intangible written offf | $ 78,864 | ||||||||
Sales milestone payments | € | € 27.5 | ||||||||
Regulatory milestone payment due | € | 2 | ||||||||
Cash upfront payment due | € | € 14 | ||||||||
Amortization expense | $ 48,503 | $ 24,826 | $ 88,948 | $ 46,023 | |||||
Approved Hormone Therapy Drug Candidate Patents [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Useful Life | 20 years | ||||||||
Domestic U.S. Patents [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 26 | 26 | |||||||
Foreign Patents [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 27 | 27 | |||||||
Domestic Utility Patents [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 12 | 12 | |||||||
Foreign Utility Patents [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 5 | 5 | |||||||
Domestic Patents - TX-004HR [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 5 | 5 | |||||||
Foreign Patents - TX-004HR [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 13 | 13 | |||||||
Domestic Utility Patent - Transdermal Patch Candidates [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 1 | 1 | |||||||
Foreign Utility Patent - Transdermal Patch Candidates [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 5 | 5 | |||||||
Domestic Utilty Patent - Opera Software [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 1 | 1 | |||||||
Domestic Utility Patents Topical - Cream Candidates [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 1 | 1 | |||||||
Domestic Patents - TX-009HR [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 2 | 2 | |||||||
Foreign Patents Progesterone - Only Candidate [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 4 | 4 | |||||||
Domestic utility patent D-limonene [Member] [Default Label] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Number of issued patents | 1 | 1 | |||||||
Subscription Agreement [Member] | Knight Therapeutics Inc. [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Issue of common stock shares (in shares) | shares | 3,921,568 | ||||||||
Gross proceeds | $ 20,000,000 | ||||||||
Common stock sale price (in dollars per share) | $ / shares | $ 5.10 | ||||||||
Minimum [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Annual net sales milestones | € | € 25 | ||||||||
Maximum [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Annual net sales milestones | € | € 100 | ||||||||
Council License Agreement [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Payment of milestone recorded as finite-lived intangible asset | $ 20,000,000,000 | ||||||||
Council License Agreement [Member] | ANNOVERA [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Milestone payments upon FDA approval | $ 20,000,000 | ||||||||
Milestone payments (payment after release of first commercial batch) | $ 20,000,000,000 | ||||||||
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent | 50.00% | ||||||||
Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent | 20.00% | ||||||||
Step-based Royalty Payment One [Member] | Council License Agreement [Member] | ANNOVERA [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Royalty (percent) | 5.00% | 5.00% | |||||||
Step-based Royalty Payment One [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Maximum [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Net sales amount per step-based royalty | $ 50,000,000 | ||||||||
Step-based Royalty Payment Three [Member] | Council License Agreement [Member] | ANNOVERA [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Royalty (percent) | 15.00% | 15.00% | |||||||
Step-based Royalty Payment Three [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Minimum [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Net sales amount per step-based royalty | $ 150,000,000 | ||||||||
Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Royalty (percent) | 10.00% | ||||||||
Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Minimum [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Net sales amount per step-based royalty | $ 50,000,000 | ||||||||
Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Maximum [Member] | |||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||
Net sales amount per step-based royalty | $ 150,000,000 |
OTHER CURRENT LIABILITIES (Deta
OTHER CURRENT LIABILITIES (Details) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Payables and Accruals [Abstract] | ||
Accrued payroll, bonuses and commission costs | $ 5,115,082 | $ 6,854,002 |
Allowance for coupons and returns | 6,340,450 | 5,294,120 |
Accrued sales and marketing costs | 2,107,696 | 2,288,028 |
Accrued compensated absences | 1,492,131 | 1,178,110 |
Allowance for wholesale distributor fees | 2,077,444 | 792,891 |
Operating lease liability - short term | 1,187,029 | |
Accrued legal and accounting expense | 367,898 | 385,824 |
Accrued research and development | 1,402,600 | 388,675 |
Accrued rent | 365,155 | |
Accrued rebates | 2,251,047 | 412,570 |
Other accrued expenses | 35,240 | 375,573 |
TOTAL OTHER CURRENT LIABILITIES | $ 22,376,617 | $ 18,334,948 |
DEBT (Details)
DEBT (Details) - USD ($) | 6 Months Ended | |
Jun. 30, 2019 | Dec. 31, 2018 | |
Schedule of debt | June 30, December 31, Financing Agreement $ 200,000,000 $ — Credit Agreement — 75,000,000 Debt discount and financing fees (5,904,780 ) (1,618,986 ) TOTAL LONG-TERM DEBT $ 194,095,220 $ 73,381,014 | |
Debt discount and financing fees | $ (5,904,780) | $ (1,618,986) |
TOTAL LONG-TERM DEBT | 194,095,220 | 73,381,014 |
Line of Credit [Member] | ||
Borrowings outstanding | $ 200,000,000 | |
Unsecured Debt [Member] | ||
Borrowings outstanding | $ 75,000,000 |
DEBT (Details Narrative)
DEBT (Details Narrative) | May 01, 2018USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | Apr. 24, 2019USD ($) | Dec. 31, 2018USD ($) |
Amortization of deferred financing fees | $ 196,734 | $ 196,734 | ||||
Deferred financing fees | 6,652,270 | 6,652,270 | ||||
Interest Expense, Borrowings | $ 3,985,000 | 3,985,000 | ||||
Amortization of debt issuance costs | $ 316,880 | $ 30,155 | ||||
Repayment fee (percent) | 4.00% | |||||
Prepayment fee (percent) | 4.00% | |||||
Effective interest rate | 11.00% | 11.00% | ||||
Repayment of debt with new credit facility | $ 81,661,000 | |||||
Line of Credit [Member] | ||||||
Borrowings outstanding | 200,000,000 | $ 200,000,000 | ||||
Long-term Debt | 200,000,000 | 200,000,000 | ||||
Unsecured Debt [Member] | ||||||
Amortization of deferred financing fees | 120,146 | |||||
Borrowings outstanding | $ 75,000,000 | |||||
Interest Expense, Borrowings | 1,816,747 | |||||
Tranche 1 [Member] | ||||||
Deferred financing fees | 6,101,513 | 6,101,513 | ||||
Term Loan [Member] | ||||||
Borrowings outstanding | 200,000,000 | 200,000,000 | ||||
Borrowing capacity under loan facility | $ 200,000,000 | |||||
Description of Interest Rate | ne-month LIBOR (subject to a LIBOR floor of1.50%) plus (ii)7.75% per annum | |||||
Basis spread of loan | 7.75% | |||||
LIBOR floor | 1.50% | |||||
Financing Agreement [Member] | ||||||
Revenues | 11,000,000 | |||||
Minimum cash balance requirement under credit agreement | $ 50,000,000 | $ 50,000,000 | ||||
Description of Interest Rate | 3-month LIBOR plus7.75% | |||||
Basis spread of loan | 7.75% | |||||
LIBOR floor rate | 2.70% | 2.70% | ||||
Facility fee paid (percent) | 2.50% | |||||
Financing Agreement [Member] | Tranche 3 [Member] | ||||||
Line of Credit Facility, Current Borrowing Capacity | $ 50,000,000 | $ 50,000,000 | ||||
Financing Agreement [Member] | Tranche 2 [Member] | ||||||
Line of Credit Facility, Current Borrowing Capacity | $ 50,000,000 | $ 50,000,000 | ||||
Financing Agreement [Member] | Subsequent Event [Member] | TSPP Facility [Member] | ||||||
Borrowing capacity under loan facility | $ 300,000,000 | |||||
Number of tranches under term loan facility | 3 | |||||
Rate [Member] | Financing Agreement [Member] | ||||||
Prime rate floor | 5.20% | 5.20% | ||||
Description of Interest Rate | the prime rate plus6.75 | |||||
Basis spread of loan | 6.75% | |||||
First Two Years [Member] | Financing Agreement [Member] | ||||||
Prepayment percent of debt | 30.00% | 30.00% | ||||
Year Three [Member] | Financing Agreement [Member] | ||||||
Prepayment percent of debt | 5.00% | 5.00% | ||||
Year Four [Member] | Financing Agreement [Member] | ||||||
Prepayment percent of debt | 3.00% | 3.00% | ||||
Year Five [Member] | Financing Agreement [Member] | ||||||
Prepayment percent of debt | 1.00% | 1.00% | ||||
Maximum [Member] | Financing Agreement [Member] | ||||||
Minimum cash balance requirement under credit agreement | $ 60,000,000 | $ 60,000,000 |
NET LOSS PER SHARE (Details)
NET LOSS PER SHARE (Details) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Anti-dilutive shares excluded from earnings per share calculation | 24,945,040 | 28,218,470 | 24,945,040 | 28,218,470 |
Warrants [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Anti-dilutive shares excluded from earnings per share calculation | 1,832,571 | 3,007,571 | 1,832,571 | 3,007,571 |
Stock Options [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Anti-dilutive shares excluded from earnings per share calculation | 22,072,469 | 25,210,899 | 22,072,469 | 25,210,899 |
Restricted Stock [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Anti-dilutive shares excluded from earnings per share calculation | 1,040,000 | 1,040,000 |
STOCKHOLDERS' EQUITY (Details)
STOCKHOLDERS' EQUITY (Details) | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Maximum [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Term | 6 years 3 months | 6 years 3 months |
Stock Options [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Risk-free interest rate - minimum | 2.19% | 2.38% |
Risk-free interest rate - maximum | 2.54% | 2.63% |
Volatility - minimum | 61.25% | 61.82% |
Volatility - maximum | 61.85% | 64.04% |
Dividend yield | 0.00% | 0.00% |
Stock Options [Member] | Minimum [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Term | 5 years 6 months | 5 years 1 month 6 days |
STOCKHOLDERS' EQUITY (Details 1
STOCKHOLDERS' EQUITY (Details 1) - Stock Options [Member] - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Options, Outstanding | ||
Options Outstanding beginning | 20,872,824 | |
Options Granted | 1,544,500 | |
Options Exercised | (288,480) | |
Options Expired | (56,375) | |
Options Outstanding ending | 22,072,469 | 20,872,824 |
Vested and Exercisable ending | 17,125,888 | |
Unvested ending | 4,946,581 | |
Options, Weighted Average Exercise Price | ||
Options Outstanding beginning | $ 4.93 | |
Granted | 4.40 | |
Exercised | 0.35 | |
Expired | 5.77 | |
Options Outstanding ending | 4.95 | $ 4.93 |
Vested and Exercisable ending | 4.79 | |
Unvested ending | $ 5.48 | |
Options, Weighted Average Remaining Contractual Life | ||
Options Outstanding | 5 years 9 months 18 days | 5 years 11 months 8 days |
Vested and Exercisable ending | 4 years 11 months 8 days | |
Unvested ending | 8 years 9 months 14 days | |
Options outstanding, Aggregate Intrinsic Value | ||
Options Outstanding beginning | $ 12,239,876 | |
Options exercised | 1,315,238 | |
Options Outstanding ending | 3,945,665 | $ 12,239,876 |
Vested and Exercisable ending | $ 3,945,665 |
STOCKHOLDERS' EQUITY (Details N
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2018 | Mar. 31, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 | |||
Preferred stock, authorized | 10,000,000 | 10,000,000 | |||
Common stock, authorized | 350,000,000 | 350,000,000 | |||
Common stock, issued | 241,221,840 | 240,462,439 | |||
Value of common stock issued during period for stock options exercised | $ 1,084,939 | $ 44,056 | $ 100,107 | ||
Number of stock options exercised (in shares) | 276,383 | ||||
Number of stock options exercised in cashless exercise (in shares) | 12,097 | 10,000 | |||
Number of common stock issued during period for stock options exercised in cashless exercise (in shares) | 11,834 | 9,841 | |||
Stock Options [Member] | |||||
Value of common stock issued during period for stock options exercised | $ 1,084,939 | $ 1,128,996 | |||
Number of stock options exercised (in shares) | 249,785 | 394,576 |
STOCKHOLDERS' EQUITY (Details_2
STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Warrants: | ||||
Warrants outstanding | $ 1,832,571 | $ 1,832,571 | ||
Weighted-average contractual remaining life | 2 years 6 months | |||
Share based compensation expense | $ 5,224,212 | $ 4,128,440 | ||
Unrecognized estimated compensation expense | $ 139,000 | $ 139,000 | ||
Outside Consultants Warrants [Member] | ||||
Warrants: | ||||
Exercise price of warrants (in dollars per share) | $ 5.63 | $ 5.63 | ||
Weighted average exercise price of warrants (in dollars per share) | 5.16 | 5.16 | ||
Warrants granted (in shares) | 75,000 | 175,000 | ||
Grant date fair value (in dollars per share) | $ 3 | $ 2.79 | ||
Share based compensation expense | $ 256,315 | |||
Expected term | 5 years | 5 years | ||
Volatility rate | 60.80% | 62.10% | ||
Risk free rate | 2.52% | 2.36% | ||
Dividend yield | 0.00% | 0.00% | ||
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised | 1,250,000 | |||
Warrants [Member] | ||||
Warrants: | ||||
Weighted average exercise price of warrants (in dollars per share) | 2.62 | 2.62 | ||
Share based compensation expense | $ 56,172 | $ 164,840 | $ 141,888 | |
Unrecognized estimated compensation expense period recognition | 18 days | |||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 471,184 | |||
Warrants [Member] | Minimum [Member] | ||||
Warrants: | ||||
Exercise price of warrants (in dollars per share) | $ 0.24 | $ 0.24 | ||
Warrants [Member] | Maximum [Member] | ||||
Warrants: | ||||
Exercise price of warrants (in dollars per share) | $ 8.20 | $ 8.20 |
STOCKHOLDERS' EQUITY (Details_3
STOCKHOLDERS' EQUITY (Details Narrative 2) - USD ($) | Dec. 13, 2018 | Jun. 30, 2019 | Mar. 31, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 |
Plan Awards Number of New Shares | 14,362,500 | 14,362,500 | |||||
Number of shares authorized for issuance | 16,812,383 | 16,812,383 | |||||
weighted average grant date (in dollars per shares) | $ 2.57 | $ 3.15 | |||||
Share-based compensation expense | $ 2,230,829 | $ 2,212,241 | $ 4,374,069 | $ 3,872,125 | |||
Total unrecognized estimated compensation expense | 11,606,000 | 11,606,000 | |||||
Shares issued for exercise of options and warrants, net | $ 100,107 | ||||||
Share based compensation expense | 5,224,212 | $ 4,128,440 | |||||
Unrecognized estimated compensation expense | $ 139,000 | $ 139,000 | |||||
Minimum [Member] | |||||||
Option exercise prices (in dollars per shares) | $ 0.10 | $ 0.10 | |||||
Maximum [Member] | |||||||
Option exercise prices (in dollars per shares) | $ 8.92 | $ 8.92 | |||||
Stock Options [Member] | |||||||
Options outstanding, ending | 22,072,469 | 22,072,469 | 20,872,824 | ||||
Recognized weighted-average period | 2 years 1 month 6 days | ||||||
Options outstanding | $ 4.95 | $ 4.95 | $ 4.93 | ||||
Options Granted | 1,544,500 | ||||||
Restricted Stock Units [Member] | |||||||
Grant date fair value (in dollars per share) | $ 4.06 | ||||||
Unrecognized estimated compensation expense | $ 3,453,000 | $ 3,453,000 | |||||
Options Granted | 1,040,000 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number | 1,040,000 | 1,040,000 | |||||
Restricted Stock [Member] | |||||||
Recognized weighted-average period | 2 years 6 months | ||||||
Share based compensation expense | $ 350,263 | $ 696,676 | |||||
Plan 2019 [Member] | |||||||
Options outstanding, ending | 637,500 | 637,500 | |||||
2012 Stock Incentive Plan [Member] | |||||||
Plan Awards Number Of New Shares Unallocated | 2,393,833 | 2,393,833 | |||||
Options outstanding, ending | 6,317,974 | 6,317,974 | |||||
2012 Stock Incentive Plan [Member] | Restricted Stock Units [Member] | |||||||
Options outstanding, ending | 1,040,000 | 1,040,000 | |||||
2009 Long Term Incentive Compensation Plan [Member] | |||||||
Plan Awards Number Of New Shares Unallocated | 56,050 | 56,050 | |||||
Options outstanding, ending | 15,116,995 | 15,116,995 |
RELATED PARTIES (Details Narrat
RELATED PARTIES (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Related Party Transaction [Line Items] | |||||
Manufacturing activities billed from related party | $ 974,000 | $ 1,266,000 | |||
Payable - related party | $ 243,000 | $ 243,000 | $ 88,000 | ||
Director [Member] | |||||
Related Party Transaction [Line Items] | |||||
Manufacturing activities billed from related party | $ 2,371,000 | $ 2,040,000 |
BUSINESS CONCENTRATIONS (Detail
BUSINESS CONCENTRATIONS (Details Narrative) - USD ($) | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Concentration Risk [Line Items] | ||
Concentration Risk | 60.00% | 71.00% |
Products Supplier #1 [Member] | Four Major Customers [Member] | ||
Concentration Risk [Line Items] | ||
Concentration Risk | 14.00% | |
Products Supplier #1 [Member] | One Major Customers [Member] | ||
Concentration Risk [Line Items] | ||
Concentration Risk | 100.00% | |
Products Supplier #2 [Member] | Four Major Customers [Member] | ||
Concentration Risk [Line Items] | ||
Concentration Risk | 18.00% | |
Products Supplier #3 [Member] | Four Major Customers [Member] | ||
Concentration Risk [Line Items] | ||
Concentration Risk | 31.00% | |
Products Supplier #4 [Member] | Four Major Customers [Member] | ||
Concentration Risk [Line Items] | ||
Concentration Risk | 37.00% | |
Customer Concentration [Member] | Sales Revenue [Member] | Minimum [Member] | ||
Concentration Risk [Line Items] | ||
Concentration Risk | 10.00% | 10.00% |
Customer Concentration - PI Services [Member] | Sales Revenue [Member] | ||
Concentration Risk [Line Items] | ||
Revenues | $ 981,000 | |
Customer Concentration - Pillpack [Member] | Sales Revenue [Member] | ||
Concentration Risk [Line Items] | ||
Revenues | $ 3,615,000 | 2,088,000 |
Customer Concentration - AmerisourceBergen [Member] | Sales Revenue [Member] | ||
Concentration Risk [Line Items] | ||
Revenues | 1,365,000 | 1,283,000 |
Customer Concentration - Cardinal Health [Member] | Sales Revenue [Member] | ||
Concentration Risk [Line Items] | ||
Revenues | $ 1,048,000 | $ 971,000 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES (Details) - USD ($) | 3 Months Ended | |
Jun. 30, 2019 | Jan. 01, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Right of use asset | $ 3,316,436 | $ 3,800,000 |
Short-term operating lease liability | 1,187,029 | |
Long-term operating lease liability | $ 2,488,101 | |
Weighted average remaining term | 5 years | |
Weighted average discount rate | 8.25% | |
Cash paid for amounts included in the measurement of lease liabilities for operating lease | $ 564,092 | |
Right-of-use assets obtained in exchange for lease obligation | $ 3,760,171 |
COMMITMENTS AND CONTINGENCIES_3
COMMITMENTS AND CONTINGENCIES (Details 1) - USD ($) | Jun. 30, 2019 | Jan. 01, 2019 |
Years ending December 31, | ||
2019 | $ 595,649 | |
2020 | 1,292,914 | |
2021 | 1,135,467 | |
2022 | 172,651 | |
2023 | 176,968 | |
Thereafter | 1,228,504 | |
Total undiscounted lease payments | 4,602,153 | |
Less: Imputed interest | (927,023) | |
Present value of lease payments | $ 3,675,130 | $ 4,100,000 |
COMMITMENTS AND CONTINGENCIES_4
COMMITMENTS AND CONTINGENCIES (Details Narrative) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2019USD ($) | Jun. 30, 2019USD ($) | |
Rental expense | $ 257,000 | $ 515,000 |
Operating lease expense | 295,000 | 590,000 |
Reimbursement from landlord - tenant improvements | 1,800,000 | 1,800,000 |
Estimated fixed future minimum rental commitment | 13,300,000 | 13,300,000 |
Estimated variable future minimum rental commitment | $ 6,400,000 | $ 6,400,000 |